← All trials
NCT04901416
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- May 25, 2021
- Last posted
- Oct 4, 2021
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Deverra Therapeutics, Inc.Lead sponsor
- Duke UniversityOverall official - principal investigator
- Duke UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.